AstraZeneca Pharma India Limited (NSE:ASTRAZEN)
India
· Delayed Price · Currency is INR 10,353
+158 (1.55%)
Jun 13, 2025, 12:31 PM IST
Revenue by Product
Fiscal year is April - March.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2016 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | 2016 - 2018 |
| Tablets | 8.71B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Tablets Growth | 15.46% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Injectables | 3.17B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Injectables Growth | 89.19% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Clinical Trials | 898.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Clinical Trials Growth | 46.83% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Inhalation | 180.70M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Inhalation Growth | -10.10% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Grant of Exclusive Distribution Rights | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is April - March.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2016 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | 2016 - 2018 |
| India | 12.02B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| India Growth | 28.01% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International | 936.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International Growth | 46.14% |
Log In |
Log In |
Log In |
Log In | Upgrade
|